How to cite item

Second-generation anaplastic lymphoma kinase inhibitors: revolutionary or evolutionary?

   
@article{JTD7711,
	author = {Dae Ho Lee},
	title = {Second-generation anaplastic lymphoma kinase inhibitors: revolutionary or evolutionary?},
	journal = {Journal of Thoracic Disease},
	volume = {8},
	number = {7},
	year = {2016},
	keywords = {},
	abstract = {Since the discovery of anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) in 2007 (1), crizotinib was developed as the first targeted therapy for patients with advanced or metastatic ALK-positive NSCLC (2). However, even though the dramatic and rapid response, most patients experienced disease progression within one year after commencement of crizotinib (3,4). To overcome crizotinib resistance, many next-generation ALK inhibitors have been developed.},
	issn = {2077-6624},	url = {https://jtd.amegroups.org/article/view/7711}
}